<SEC-DOCUMENT>0001840315-23-000004.txt : 20230526
<SEC-HEADER>0001840315-23-000004.hdr.sgml : 20230526
<ACCEPTANCE-DATETIME>20230526095745
ACCESSION NUMBER:		0001840315-23-000004
CONFORMED SUBMISSION TYPE:	144/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230526
DATE AS OF CHANGE:		20230526

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		23963672

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ocumension Therapeutics
		CENTRAL INDEX KEY:			0001840315
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144/A

	BUSINESS ADDRESS:	
		STREET 1:		56F, ONE MUSEUM PLACE
		STREET 2:		669 XIN ZHA ROAD
		CITY:			JING'AN DISTRICT, SHANGHAI
		STATE:			F4
		ZIP:			200041
		BUSINESS PHONE:		862122893688

	MAIL ADDRESS:	
		STREET 1:		56F, ONE MUSEUM PLACE
		STREET 2:		669 XIN ZHA ROAD
		CITY:			JING'AN DISTRICT, SHANGHAI
		STATE:			F4
		ZIP:			200041

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OcuMension Therapeutics
		DATE OF NAME CHANGE:	20210113
</SEC-HEADER>
<DOCUMENT>
<TYPE>144/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144/A</submissionType>
    <previousAccessionNumber>0001968940-23-000001</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001840315</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001314102</issuerCik>
      <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
      <secFileNumber>000-51122</secFileNumber>
      <issuerAddress>
        <com:street1>480 PLEASANT STREET</com:street1>
        <com:street2>SUITE B300</com:street2>
        <com:city>WATERTOWN</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02472</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-926-5000</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Ocumension Therapeutics</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Tiger Brokers (Singapore) Pte. Ltd.  Singapore</name>
        <address>
          <com:street1>1 Raffles Place, #35-61</com:street1>
          <com:street2>One Raffles, Place Tower 2,</com:street2>
          <com:city>Singapore</com:city>
          <com:stateOrCountry>U0</com:stateOrCountry>
          <com:zipCode>048616</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1</noOfUnitsSold>
      <aggregateMarketValue>5.93</aggregateMarketValue>
      <noOfUnitsOutstanding>37312647</noOfUnitsOutstanding>
      <approxSaleDate>05/26/2023</approxSaleDate>
      <securitiesExchangeName>Nasdaq</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>12/31/2020</acquiredDate>
      <natureOfAcquisitionTransaction>Through a private placement from the issuer of the securities</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Eyepoint Pharmaceuticals, Inc.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>3010722</amountOfSecuritiesAcquired>
      <paymentDate>12/31/2020</paymentDate>
      <natureOfPayment>Good funds</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>This Form 144/A is being filed to amend the Form 144 filed on May 26, 2023 to change (i) the Number of Shares or Other Units to Be Sold from 3010722 to 1, (ii) the Aggregate Market Value from 17853581.46 to 5.93 and (iii) the Number of Shares or Other Units Outstanding from 34301926 to 37312647.</remarks>
    <noticeSignature>
      <noticeDate>05/26/2023</noticeDate>
      <signature>YE LIU</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
